2026 · 2nd Quarter (Apr 1 - June 30)

VERTEX PHARMACEUTICALS INCORPORATED

Filed by AVENUE SOLUTIONS.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 20, 2026
Income: $60,000.00
Expenses: Not reported
Registrant: AVENUE SOLUTIONS
Client: VERTEX PHARMACEUTICALS INCORPORATED
Filing UUID: c314ceff-093e-4b03-a15f-879635f5524e
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process; Kidney care issues; FY27 LHHS and Mil-Con appropriations report language

Literal federal measure citations: H.R. 1227, S. 475

HCR · Health Issues

Monitor issues related to 340b;

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.